Kottil W. Rammohan
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Area:
Neuroscience Biology, Molecular Biology, ImmunologyGoogle:
"Kottil Rammohan"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Vermersch P, Giovannoni G, Sørensen PS, et al. (2020) Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study Multiple Sclerosis and Related Disorders. 37: 101602 |
| Giovannoni G, Soelberg Sorensen P, Cook S, et al. (2017) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517727603 |
| Giovannoni G, Rammohan K, Cook S, et al. (2017) PO138 High disease activity in relapsing multiple sclerosis (rms) Journal of Neurology, Neurosurgery, and Psychiatry. 88 |
| Hadjixenofontos A, Beecham AH, Manrique CP, et al. (2015) Clinical Expression of Multiple Sclerosis in Hispanic Whites of Primarily Caribbean Ancestry. Neuroepidemiology. 44: 262-8 |
| Delgado SR, Lavi ES, Campos YA, et al. (2014) Natalizumab Associated PML in a Multiple Sclerosis Patient: Excellent Response to Minimal Intervention Journal of Multiple Sclerosis. 1: 1-4 |
| Rammohan K, Giovannoni G, Comi G, et al. (2012) Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders. 1: 49-54 |
| Ortega MR, Usmani N, Parra-Herran C, et al. (2012) CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma. Neurology. 79: 715-6 |
| Rammohan KW, Ortega MR, Delgado SR, et al. (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 77: 1930; discussion 193 |
| Giovannoni G, Cook S, Rammohan K, et al. (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis Lancet Neurology. 10: 329-337 |
| Giovannoni G, Comi G, Cook S, et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England Journal of Medicine. 362: 416-26 |